www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the

PowerPoint Presentation 1 MANAGEMENT DISCUSSION & ANALYSIS Q1/2023 A f t e r Y o u P u b l i c C o m p a n y L i m i t e d Financial Performance Management Discussion & Analysis Q1/2023 Executive

Food Holding Co., Ltd. is a spouse of a director and an executive of EIC.The independent financial advisor (IFA) is of the view that the shareholders should not approve the transaction because the

ทั้งหมด ปกหน้า 21 เมษายน 2565 [ส่วนที่ 1] - ข้อมูลสรุป (Executive Summary) 21 เมษายน 2565 [ส่วนที่ 2.1] - วัตถุประสงค์การใช้เงิน 21 เมษายน 2565 [ส่วนที่ 2.2] - โครงสร้างและการดำเนินงานของกลุ่มบริษัท 21

supporting the protection of investor personal data, to ease the burden of cost of the investors to repeatedly provide such data when switching their services.Mr. Boonsun Prasitsumrit, Chief Executive

K e y F i n a n c i a l H i g h l i g h t s 1 1EBITDA Margin and Net Profit Margin are calculated from Total Revenue Executive S u m m a r y : • The Company reported net profit in Q1/2024 of THB 54

: Director and General Manager The Stock Exchange of Thailand Eureka Design Public Company Limited and its subsidiaries (“the Group”) would like to clarify the changes in excess of 20% in the Group’s operating

O.C.C. Public Company Limited No. 3/2561 on December 15, 2018 considered and has pass a resolution to approve the transaction of warehouse lease with related persons as following detail: 1. Transaction

of Thailand Major Development Public Company Limited (“The Company”) would like to inform total revenues 1,982.10 million baht and net profit 200.83 million baht in the consolidated financial statement

(Thailand) Public Company Limited (“INGRS” or “the Company”) would like to provide an explanation about our 3-months financial performance for the period ended 30 April 2020: 1. Sales Revenue INGRS registered